Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a report released on Wednesday. They currently have a $12.00 price target on the stock, down from their previous price target of $32.00. Jefferies Group LLC’s target price indicates a potential upside of 57.89% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Canaccord Genuity set a $35.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 13th. Roth Capital set a $30.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 target price on shares of Zynerba Pharmaceuticals in a research note on Tuesday, May 9th. Maxim Group set a $32.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 26th. Finally, HC Wainwright set a $30.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $17.89.

Zynerba Pharmaceuticals (ZYNE) traded up 21.21% during trading on Wednesday, reaching $7.60. 4,310,435 shares of the company’s stock were exchanged. Zynerba Pharmaceuticals has a 12 month low of $6.20 and a 12 month high of $25.95. The firm has a 50 day moving average of $17.54 and a 200-day moving average of $19.50. The stock’s market cap is $100.75 million. Zynerba Pharmaceuticals also was the recipient of unusually large options trading on Monday. Stock traders bought 7,953 put options on the company. This is an increase of 726% compared to the typical daily volume of 963 put options.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.04. On average, equities research analysts anticipate that Zynerba Pharmaceuticals will post ($2.46) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zynerba Pharmaceuticals’ (ZYNE) Buy Rating Reaffirmed at Jefferies Group LLC” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/zynerba-pharmaceuticals-zyne-buy-rating-reaffirmed-at-jefferies-group-llc/1466538.html.

In other Zynerba Pharmaceuticals news, CFO James E. Fickenscher acquired 5,200 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were bought at an average cost of $19.82 per share, with a total value of $103,064.00. Following the completion of the transaction, the chief financial officer now directly owns 12,200 shares of the company’s stock, valued at approximately $241,804. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Armando Anido acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were acquired at an average cost of $19.70 per share, for a total transaction of $98,500.00. Following the completion of the transaction, the chairman now directly owns 336,012 shares of the company’s stock, valued at $6,619,436.40. The disclosure for this purchase can be found here. Company insiders own 10.02% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. acquired a new stake in Zynerba Pharmaceuticals during the first quarter valued at approximately $9,362,000. JPMorgan Chase & Co. boosted its stake in Zynerba Pharmaceuticals by 65,190.0% in the second quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock valued at $5,539,000 after buying an additional 325,950 shares during the period. Vanguard Group Inc. boosted its stake in Zynerba Pharmaceuticals by 53.9% in the first quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock valued at $8,559,000 after buying an additional 149,094 shares during the period. Pennsylvania Trust Co acquired a new stake in Zynerba Pharmaceuticals during the second quarter valued at approximately $2,366,000. Finally, Sphera Funds Management LTD. acquired a new stake in Zynerba Pharmaceuticals during the first quarter valued at approximately $2,010,000. 31.08% of the stock is currently owned by institutional investors.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.